AstraZeneca的Imfinzi癌症药物接受林业发展局对有限阶段小细胞肺癌的优先审查。 AstraZeneca's Imfinzi cancer drug receives priority FDA review for limited-stage small cell lung cancer.

AstraZeneca's Imfinzi, 一种封锁型癌症药物, 接受美国食品与药物管理局的优先审查, AstraZeneca's Imfinzi, a blockbuster cancer drug, receives priority review from the U.S. FDA for limited-stage small cell lung cancer patients in the US. 根据积极的晚期数据,FDA的决定日期为2024年第四季度,该数据显示Imfinzi改善了基于的同时化学放射治疗后没有进展的肺癌患者的整体生存率和无进展生存率. The FDA's decision date is set for Q4 2024, based on positive late-stage data showing Imfinzi improves overall survival and progression-free survival for lung cancer patients who haven't progressed after platinum-based concurrent chemoradiotherapy. Imfinzi是人类单克隆抗体,通过堵住肿瘤免疫规避,同时增加抗癌免疫反应,提供化疗的替代办法。 Imfinzi is a human monoclonal antibody that works by blocking tumor immune evasion while boosting anti-cancer immune response, offering an alternative to chemotherapy.